Dr. Kamran Honarnejad

Angestellt, Group Leader - Target Identification and Validation, In vitro Biology, Evotec SE
Hamburg, Germany

Fähigkeiten und Kenntnisse

Drug Discovery
High Throughput Screening
High Content Screening
CRISPR
RNAi
Chemogenomics
Assay Development
iPS-derived models
Organoids
Phenotypic Drug Discovery
Hit-to-lead
Lead Optimization
Small molecule drug discovery
Neurodegeneration
Oncology
Immuno-oncology
Brain and CNS
Sample management
Liquid handling
Lab Automation
Cell-based assays
Cellular Assays
Biochemical Assays
High-content Imaging
Target Identification
Target Validation
CRISPR Screening
RNAi Screening
Compound Screening
Precision Medicine
Co-culture models
Disease-relevant models
Cell Painting
Hit Profiling
Compound Profiling
In Vitro Pharmacology
3D cell culture
Research and Development
Project Leadership
CRO
Biotech
Pharma
Pipetting Robots
Venture Capital
Integrated Drug Discovery
Leadership
Innovation
Project Management
Matrix project management
Group Leadership

Werdegang

Berufserfahrung von Kamran Honarnejad

  • Current 4 years and 5 months, since Jan 2022

    Group Leader - Target Identification and Validation, In vitro Biology

    Evotec SE

    - Target identification and validation by CRISPR technology across therapeutic area - Scientific, technical and operational project leadership of multiple client and internal projects

  • 4 years and 4 months, Sep 2017 - Dec 2021

    Group Leader - High-Throughput Drug and Target Discovery

    Fraunhofer ITEM

    - High-throughput chemical biology (small molecule) and genetic loss of function (RNAi and CRISPR/Cas9) screening for drug and target discovery in patient-derived preclinical cellular models of cancer; Personalized tumor therapy and rare diseases - Automated platform for optimization of growth conditions for cultivation of patient-derived cancer cells

  • 4 years and 3 months, May 2013 - Jul 2017

    Project Leader - CNS Discovery (Neuroallianz Public-Private Partneship)

    Uniklinik Bonn

    - Scientific and Operational Project Leadership, Neuroallianz Public Private Partnership Consortium, N2/N2B Therapeutic Project (Partners: University Bonn, Institute of Pharmacology and Toxicology and UCB Pharma) Project: "Identification of novel drug targets for neurodegenerative diseases by RNAi screening" - High-throughput screening facility leader - Lecturer and coordinator of Neuropharmacology course

  • 5 years and 5 months, Dec 2007 - Apr 2013

    PhD Candidate

    Klinikum der LMU München

    PhD project in Neuroscience Project: “Discovery and characterization of novel drugs for treatment of Alzheimer’s disease from a high-throughput compound screen”

  • 2 months, Jul 2008 - Aug 2008

    Intern

    Center for Genomic Regulation Barcelona (CRG)

    Project: "Computational studies on functional aspects of chromatin organization in a set of 41 hormone- inducible human genes"

  • 8 months, Oct 2006 - May 2007

    M.Sc. Thesis Student

    German Cancer Research Center Heidelberg (DKFZ)

    Project: "Identification and characterization of required factors for active DNA demethylation"

  • 7 months, Nov 2005 - May 2006

    Intern

    Center for Molecular Biology, University of Heidelberg

    Project: "Identification of responsive and initiative genes in Alzheimer’s disease triggered by alterations of the Aβ42/Aβ40 ratio"

  • 3 months, Jul 2005 - Sep 2005

    Intern

    University Hospital Mannheim, Univ. of Heidelberg

    Project: "Studies on gene expression in individual rat cerebral artery endothelial cells using RT-PCR"

  • 9 months, Sep 2004 - May 2005

    B.Sc. Thesis Student

    Center for Molecular Biology, University of Heidelberg

    Project: "Expression profiling of astroglial-induced neurotransdifferentation of human multipotent adult progenitor Cells (MAPCs) using MELK technology"

  • 5 months, Aug 2003 - Dec 2003

    Intern

    EMBL (European Molecular Biology Laboratory)

    "Mechanisms of transcription regulation through chromatin"

  • 3 months, Jul 2002 - Sep 2002

    Intern

    The Centre for Green Genetic Engineering (CGG)

    Project: "Molecular Characterisation of the Arabis mosaic nepovirus"

Ausbildung von Kamran Honarnejad

  • 4 years and 6 months, Oct 2008 - Mar 2013

    Systemic Neurosciences

    Ludwig Maximilian University Munich (LMU)

  • 1 year and 11 months, Oct 2005 - Aug 2007

    Biotechonology

    Mannheim University of Applied Sciences

    Biomedical Biotechnology

  • 4 years, Oct 2001 - Sep 2005

    Biotechonology

    Mannheim University of Applied Sciences

Sprachen

  • English

    C1 (Fließend)

  • German

    B1-B2 (Gute Kenntnisse)

  • Persian

XING – Das Jobs-Netzwerk

  • Über eine Million Jobs

    Entdecke mit XING genau den Job, der wirklich zu Dir passt.

  • Persönliche Job-Angebote

    Lass Dich finden von Arbeitgebern und über 20.000 Recruiter·innen.

  • 21 Mio. Mitglieder

    Knüpf neue Kontakte und erhalte Impulse für ein besseres Job-Leben.

  • Kostenlos profitieren

    Schon als Basis-Mitglied kannst Du Deine Job-Suche deutlich optimieren.

21 Mio. XING Mitglieder, von A bis Z